PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$41.34

16 May
2022

0.320

OPEN

$40.86

0.78%

HIGH

$42.29

156,944

LOW

$40.58

TARGET
$51.10 23.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx 29.6 42.8 xxx
DPS (cps) xxx 15.0 20.2 xxx
EPS Growth xxx 33.4% 44.3% xxx
DPS Growth xxx 25.0% 34.7% xxx
PE Ratio xxx N/A 93.4 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 50.6% 47.3% xxx

Dividend yield today if purchased 3 years ago: 0.75%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.38

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/03 - ex-div 10c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx29.6
DPS All xxxxxxxxxxxxxxx15.0
Sales/Revenue xxxxxxxxxxxxxxx67.9 M
Book Value Per Share xxxxxxxxxxxxxxx78.4
Net Operating Cash Flow xxxxxxxxxxxxxxx39.0 M
Net Profit Margin xxxxxxxxxxxxxxx45.45 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx43.49 %
Return on Invested Capital xxxxxxxxxxxxxxx42.36 %
Return on Assets xxxxxxxxxxxxxxx27.89 %
Return on Equity xxxxxxxxxxxxxxx43.49 %
Return on Total Capital xxxxxxxxxxxxxxx57.75 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx25.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

17/02/2022

1

Add

$56.20

35.95%

Pro Medicus' December-half results outpaced consensus and Morgans' forecasts, EBIT margin forecasts massively outpacing, as strong operating leverage dwarfed expenses growth.

Pro Medicus's pipeline continued to grow in the half, Morgans citing both depth and mix and a strong shift towards the cloud.

Morgans says the business has never been in better shape and the recent share-price correction offers an attractive entry point.

Add rating retained. Target price rises to $56.20 from $54.49.

FORECAST
Morgans forecasts a full year FY22 dividend of 20.00 cents and EPS of 45.00 cents.
Morgans forecasts a full year FY23 dividend of 24.00 cents and EPS of 52.00 cents.
Access Stockbroker Research History >

PME STOCK CHART

FNArena News on PME

1
Australian Broker Call *Extra* Edition – Apr 13, 2022

Apr 13 2022 - Daily Market Reports
2
Rudi’s View: Peter’s Portfolio Reviewed

Apr 13 2022 - Rudi's View
3
Rudi’s View: Too Many Distractions From Corporate Results

Mar 03 2022 - Rudi's View
4
Rudi’s View: More Beats Than Misses

Feb 24 2022 - Rudi's View
5
Australian Broker Call *Extra* Edition – Feb 18, 2022

Feb 18 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia